Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2017 | Pages:
120 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Chemotherapy Induced Neutropenia - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H2 2017, provides an overview of the Chemotherapy Induced Neutropenia (Toxicology) pipeline landscape. Chemotherapy-induced neutropenia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness and abdominal pain. The predisposing factors include age, co-morbidities and time course of therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Neutropenia (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Chemotherapy Induced Neutropenia (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 4, 2, 5, 6, 9, 14 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively. Chemotherapy Induced Neutropenia (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia (Toxicology). - The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Neutropenia (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Chemotherapy Induced Neutropenia (Toxicology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Chemotherapy Induced Neutropenia (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Neutropenia (Toxicology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Neutropenia (Toxicology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia (Toxicology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Chemotherapy Induced Neutropenia - Overview 7 Chemotherapy Induced Neutropenia - Therapeutics Development 8 Pipeline Overview 8 Pipeline by Companies 9 Pipeline by Universities/Institutes 12 Products under Development by Companies 13 Products under Development by Universities/Institutes 16 Chemotherapy Induced Neutropenia - Therapeutics Assessment 17 Assessment by Target 17 Assessment by Mechanism of Action 19 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Chemotherapy Induced Neutropenia - Companies Involved in Therapeutics Development 25 BeyondSpring Pharmaceuticals Inc 25 Biocon Ltd 25 Bolder Biotechnology Inc 26 Cellerant Therapeutics Inc 26 Chong Kun Dang Pharmaceutical Corp 27 Cinfa Biotech SL 27 Dr. Reddy's Laboratories Ltd 28 Gene Techno Science Co Ltd 28 Generon (Shanghai) Corp Ltd 29 Genexine Inc 29 GlycoMimetics Inc 30 Hanmi Pharmaceuticals Co Ltd 30 Intas Pharmaceuticals Ltd 31 Lupin Ltd 31 Mycenax Biotech Inc 32 Myelo Therapeutics GmbH 32 Nohla Therapeutics Inc 33 Octapharma AG 33 Pangen Biotech Inc. 34 Pfenex Inc 34 Pfizer Inc 35 Reliance Life Sciences Pvt Ltd 35 Richter Gedeon Nyrt 36 Sandoz International GmbH 36 USV Pvt Ltd 37 Chemotherapy Induced Neutropenia - Drug Profiles 38 BBT-007 - Drug Profile 38 BBT-015 - Drug Profile 39 BBT-018 - Drug Profile 40 Cell Therapy for Chemotherapy Induced Neutropenia - Drug Profile 41 Cell Therapy for Chemotherapy Induced Neutropenia - Drug Profile 42 EC-18 - Drug Profile 43 eflapegrastim - Drug Profile 45 F-627 - Drug Profile 48 filgrastim - Drug Profile 50 filgrastim - Drug Profile 51 filgrastim - Drug Profile 53 filgrastim - Drug Profile 54 filgrastim - Drug Profile 55 filgrastim - Drug Profile 56 filgrastim - Drug Profile 57 filgrastim - Drug Profile 58 GMI-1271 - Drug Profile 59 GW-003 - Drug Profile 67 HSA-GCSF - Drug Profile 68 lenograstim - Drug Profile 69 Myelo-001 - Drug Profile 70 pegfilgrastim - Drug Profile 72 pegfilgrastim - Drug Profile 74 pegfilgrastim - Drug Profile 75 pegfilgrastim - Drug Profile 76 pegfilgrastim - Drug Profile 77 pegfilgrastim - Drug Profile 78 pegfilgrastim - Drug Profile 79 pegfilgrastim - Drug Profile 80 pegfilgrastim - Drug Profile 81 pegfilgrastim - Drug Profile 82 pegfilgrastim - Drug Profile 83 pegfilgrastim - Drug Profile 84 pegfilgrastim - Drug Profile 85 pegfilgrastim - Drug Profile 86 pegfilgrastim - Drug Profile 87 pegfilgrastim - Drug Profile 89 pegfilgrastim - Drug Profile 90 plinabulin - Drug Profile 91 romyelocel-L - Drug Profile 97 WBI-2100 - Drug Profile 100 YPEG-Filgrastim - Drug Profile 101 Chemotherapy Induced Neutropenia - Dormant Projects 102 Chemotherapy Induced Neutropenia - Discontinued Products 104 Chemotherapy Induced Neutropenia - Product Development Milestones 105 Featured News & Press Releases 105 Appendix 116 Methodology 116 Coverage 116 Secondary Research 116 Primary Research 116 Expert Panel Validation 116 Contact Us 116 Disclaimer 117
List of Tables
Number of Products under Development for Chemotherapy Induced Neutropenia, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Chemotherapy Induced Neutropenia - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2017 Chemotherapy Induced Neutropenia - Pipeline by Biocon Ltd, H2 2017 Chemotherapy Induced Neutropenia - Pipeline by Bolder Biotechnology Inc, H2 2017 Chemotherapy Induced Neutropenia - Pipeline by Cellerant Therapeutics Inc, H2 2017 Chemotherapy Induced Neutropenia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017 Chemotherapy Induced Neutropenia - Pipeline by Cinfa Biotech SL, H2 2017 Chemotherapy Induced Neutropenia - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2017 Chemotherapy Induced Neutropenia - Pipeline by Gene Techno Science Co Ltd, H2 2017 Chemotherapy Induced Neutropenia - Pipeline by Generon (Shanghai) Corp Ltd, H2 2017 Chemotherapy Induced Neutropenia - Pipeline by Genexine Inc, H2 2017 Chemotherapy Induced Neutropenia - Pipeline by GlycoMimetics Inc, H2 2017 Chemotherapy Induced Neutropenia - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017 Chemotherapy Induced Neutropenia - Pipeline by Intas Pharmaceuticals Ltd, H2 2017 Chemotherapy Induced Neutropenia - Pipeline by Lupin Ltd, H2 2017 Chemotherapy Induced Neutropenia - Pipeline by Mycenax Biotech Inc, H2 2017 Chemotherapy Induced Neutropenia - Pipeline by Myelo Therapeutics GmbH, H2 2017 Chemotherapy Induced Neutropenia - Pipeline by Nohla Therapeutics Inc, H2 2017 Chemotherapy Induced Neutropenia - Pipeline by Octapharma AG, H2 2017 Chemotherapy Induced Neutropenia - Pipeline by Pangen Biotech Inc., H2 2017 Chemotherapy Induced Neutropenia - Pipeline by Pfenex Inc, H2 2017 Chemotherapy Induced Neutropenia - Pipeline by Pfizer Inc, H2 2017 Chemotherapy Induced Neutropenia - Pipeline by Reliance Life Sciences Pvt Ltd, H2 2017 Chemotherapy Induced Neutropenia - Pipeline by Richter Gedeon Nyrt, H2 2017 Chemotherapy Induced Neutropenia - Pipeline by Sandoz International GmbH, H2 2017 Chemotherapy Induced Neutropenia - Pipeline by USV Pvt Ltd, H2 2017 Chemotherapy Induced Neutropenia - Dormant Projects, H2 2017 Chemotherapy Induced Neutropenia - Dormant Projects, H2 2017 (Contd..1), H2 2017 Chemotherapy Induced Neutropenia - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
